Sarcomas and the Immune System: Implications for Therapeutic Strategies

Surgical Oncology Clinics of North America

Volumn 21, Issue 2, 2012, Pages 341-355

  Francescutti, Valerie ^a   Skitzki, Joseph J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antigen; Immunoediting; Immunotherapy; Sarcoma; Vaccine

Indexed keywords

3 METHYLCHOLANTHRENE; ANTIRETROVIRUS AGENT; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 12; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL EXPANSION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; EWING SARCOMA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; HYPERTHERMIC THERAPY; IMMUNE DEFICIENCY; INNATE IMMUNITY; KAPOSI SARCOMA; LOCAL RECURRENCE FREE SURVIVAL; LUNG METASTASIS; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SURVIVAL TIME; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; FORECASTING; HUMANS; IMMUNE SYSTEM; IMMUNITY, CELLULAR; IMMUNOTHERAPY; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 84857380053     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2011.11.002     Document Type: Review

References (85)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Gibault L., Perot G., Chibon F., et al. New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol 2011, 223:64-71.
3. Randall R.L., Bruckner J.D., Papenhausen M.D., et al. Errors in diagnosis and margin determination of soft-tissue sarcomas initially treated at non-tertiary centers. Orthopedics 2004, 27(2):209-212.
4. McCarthy E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006, 26:154-158.
5. Coley W.B. The treatment of malignant tumors by repeated inoculations of Erysipelas: with a report of ten original cases. Am J Med Sci 1893, 10:487-511.
6. Coley W.B. Contribution to the knowledge of sarcoma. Ann Surg 1891, 14:199-220.
7. The failure of the erysipelas toxins. JAMA 1894, 24:919. [editorial].
8. Coley-Nauts H., McLaren J.R. Coley toxins-the first century. Adv Exp Med Biol 1990, 267:483-500.
9. Johnston B., Novales E.T. Clinical effects of Coley's toxin: a seven year study. Cancer Chemother Rep 1962, 21:43-68.
10. Carswell E.A., Old L.J., Kassel R.L., et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72(9):3666-3670.
11. Tsung K., Norton J.A. Lessons from Coley's toxin. Surg Oncol 2006, 15(1):25-28.
12. Burnet F.M. Cancer-a biological approach. Br Med J 1957, 1:841-847.
13. Burnet F.M. Immunological factors in the process of carcinogenesis. Br Med Bull 1964, 20:154-158.
14. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res 1970, 13:1-127.
15. Dunn G.P., Bruce A.T., Ikeda H., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3(11):991-998.
16. Koebel C.M., Vermi W., Swann J.B., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450(7171):903-907.
17. Swann J.B., Vesely M.D., Silva A., et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A 2008, 105(2):652-658.
18. Zhang L., Conejo-Garcia J.R., Katsaros D., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cells. N Engl J Med 2003, 348(3):203-213.
19. Berghuis D., Santos S.J., Baelde H.J., et al. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol 2011, 223(3):347-357.
20. hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int J Cancer 2009, 125(4):879-886.
21. Dalen B.P., Geijer M., Kvist H., et al. Clinical and imaging observations of desmoid tumors left without treatment. Acta Orthoped 2006, 77(6):932-937.
22. Nakayama T., Tsuboyama T., Toguchida J., et al. Natural course of desmoid-type fibromatosis. J Orthop Sci 2008, 13(1):51-55.
23. Matsuo T., Shimose S., Kubo T., et al. Extraskeletal osteosarcoma with partial spontaneous regression. Anticancer Res 2009, 29:5197-5202.
24. Noria S., David A., Kandel R., et al. Residual disease following unplanned excision of a soft-tissue sarcoma of an extremity. J Bone Joint Surg 1996, 78(5):650-655.
25. Lewis J.J., Leung D., Espat J., et al. Effect of reresection in extremity soft tissue sarcoma. Ann Surg 2000, 5:655-663.
26. Tsukahara T., Kawaguchi S., Torigoe T., et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006, 97(12):1374-1380.
27. Mitchell M.S. Immunology of sarcomas. Clin Orthop Rel Res 1980, 153:26-30.
28. Morton D.L., Malmgren R.A. Human osteosarcomas: immunologic evidence suggesting an associated infectious agent. Science 1968, 162(3859):1279-1281.
29. Morton D.L., Malmgren R.A., Hall W.T., et al. Immunologic and virus studies with human sarcomas. Surgery 1969, 66(1):152-161.
30. Wood W.C., Morton D.L. Host immune response to a common cell-surface antigen in human sarcomas: detection by cytotoxicity tests. N Engl J Med 1971, 284(11):569-572.
31. Gupta R.K., Morton D.L. Detection of cancer-associated antigen(s) in urine of sarcoma patients. J Surg Oncol 1979, 11(1):65-74.
32. Mesri E.A., Cesarman E., Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010, 10:707-719.
33. Ledergerber B., Telenti A., Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. Br Med J 1999, 319:23-24.
34. Wilkinson J., Cope A., Gill J., et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 2002, 76(6):2634-2640.
35. Gill J., Bourboulia D., Wilkinson J., et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002, 31:384-390.
36. DeLeo A.B., Jay G., Appella E., et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A 1979, 76(5):2420-2424.
37. North R.J., Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. J Exp Med 1984, 159:1295-1311.
38. Shu S., Rosenberg S.A. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res 1985, 45:1657-1662.
39. Chou T., Chang A.E., Shu S. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization: culture requirements and characterization of immunologic specificity. J Immunol 1988, 140(7):2453-2461.
40. Shu S., Rosenberg S.A. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J Immunol 1985, 135(4):2895-2903.
41. Chou T., Bertera S., Chang A.E., et al. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J Immunol 1988, 141(5):1775-1781.
42. Basse P., Herberman R.B., Nannmark U., et al. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 1991, 174(2):479-488.
43. Shiloni E., Lafreniere R., Mule J.J., et al. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice. Cancer Res 1986, 46(11):5633-5640.
44. Sabel M.S., Arora A., Su G., et al. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic antitumor immunity is mediated by both CD8+ CTL and NK cells. Surgery 2007, 142(5):749-760.
45. Guo Q.Y., Yuan M., Peng J., et al. Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma. J Exp Clin Cancer Res 2011, 30(1):24-30.
46. Tevz G., Kranjc S., Cemazar M., et al. Controlled systemic release of interleukin-12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas. J Gene Med 2009, 11(12):1125-1137.
47. Kennel S.J., Lankford T., Flynn K.M. Therapy of a murine sarcoma using syngeneic monoclonal antibody. Cancer Res 1983, 43:2843-2848.
48. Kennel S.J., Lankford P.K., Flynn K.M., et al. Factors affecting passive monoclonal antibody therapy of Moloney sarcoma in BALB/c mice. Cancer Res 1985, 45:3782-3789.
49. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nature Med 2004, 10(9):909-915.
50. Marcove R.C., Mike V., Huvos A.G., et al. Vaccine trials for osteogenic sarcoma: a preliminary report. CA Cancer J Clin 1973, 23(2):74-80.
51. Marcove R.C., Southam C.M., Levin A., et al. A clinical trial of autogenous vaccine in osteogenic sarcoma in patients under the age of twenty-five. Surg Forum 1971, 22:434-435.
52. Dillman R.O., Wiemann M., Nayak S.K., et al. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group. J Immunother 2003, 26(4):367-373.
53. Morgan J., Spendlove I., Durrant L.G. The role of CD55 in protecting the tumour environment from complement attack. Tissue Antigens 2002, 60(3):213-223.
54. Pritchard-Jones K., Spendlove I., Wilton C., et al. Douglas, and. Immune response to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br J Cancer 2005, 92:1358-1365.
55. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383.
56. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
57. Geiger J., Hutchinson R., Hohenkirk L., et al. Treatment of solid tumors in children with tumor-lysate-pulsed dendritic cells. Lancet 2000, 356:1163-1165.
58. Matsuzaki A., Suminoe A., Hattori H., et al. Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J Pediatr Hematol Oncol 2002, 24(3):220-223.
59. Mackall C.L., Rhee E.H., Read E.J., et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 2008, 14(15):4850-4858.
60. Maki R.G. Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol 2006, 18:363-368.
61. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993, 90:3539-3543.
62. Mahvi D.M., Shi F.S., Yang N.S., et al. Immunization by particle-mediated transfer of the granulocyte-macrophage colony stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study. Hum Gene Ther 2002, 13:1711-1721.
63. Dagher R., Long L.M., Read E.J., et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-interinstitute NIH study. Med Pediatr Oncol 2002, 38:158-164.
64. Lindquist S. The heat shock response. Annu Rev Biochem 1986, 55:1151-1191.
65. Chirico W.J., Waters M.G., Blobel G. 70K heat shock related proteins stimulate protein translocation into microsomes. Nature 1988, 332:805-810.
66. Vanbuskirk A., Crump B.L., Margoliash E., et al. A peptide binding protein having a role in antigen presentation is a member of the HSP70 heat shock family. J Exp Med 1989, 170:1799-1809.
67. Multhoff G., Botzler C., Wiesnet M., et al. A stress-inducible 72-kDa heat shock protein (HSP 72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer 1995, 61:272-279.
68. Multhoff G., Botzler C., Wiesnet M., et al. CD3- large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heat shock protein on human sarcoma cells. Blood 1995, 86(4):1374-1382.
69. Multhoff G. Heat shock protein 72 (HSP72), a hyperthermia inducible immunogenic determinant on leukemic K562 and Ewing's sarcoma cells. Int J Hyperthermia 1997, 13(1):39-48.
70. Issels R.D., Lindner L.H., Verweij J., et al. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG): European Society for Hyperthermic Oncology (ESHO). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft tissue sarcoma: a randomized phase 3 multicenter study. Lancet Oncol 2010, 11(6):561-570.
71. Otsuka T., Yonezawa M., Kamiyama F., et al. Results of surgery and radio-hyperthermo-chemotherapy for patients with soft tissue sarcoma. Int J Clin Oncol 2001, 6(5):253-258.
72. Geehan D.M., Fabian D.F., Lefor A.T. Immunotherapy and whole body hyperthermia as combined modality treatment of a subcutaneous murine sarcoma. J Surg Oncol 1993, 53:180-183.
73. Strauch E.D., Fabian D.F., Turner J., et al. Combined hyperthermia and immunotherapy treatment of multiple pulmonary metastases in mice. Surg Oncol 1994, 3:45-52.
74. Gattinoni L., Powell D.J., Rosenberg S.A., et al. Adoptive immunotherapy for cancer: building on success. Nature Immunol 2006, 6:383-393.
75. Rosenberg S.A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233:1318-1321.
76. Schiltz P.M., Beutel L.D., Nayak S.K., et al. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. J Immunother 1997, 20(5):377-386.
77. Cho D., Shook D.R., Shimasaki N., et al. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010, 16:3901-3909.
78. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182:459-465.
79. Daftarian P., Song G.Y., Ali S., et al. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res 2004, 64:5407-5414.
80. Hurwitz A.A., Foster B.A., Kwon E.D., et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000, 60:2444-2448.
81. Espenschied J., Lamont J., Longmate J., et al. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 2003, 170:3401-3407.
82. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
83. Ayyoub M., Taub R.N., Keohan M.L., et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004, 4:7-14.
84. Todd R., Lunec J. Molecular pathology and potential therapeutic targets in soft-tissue sarcoma. Expert Rev Anticancer Ther 2008, 8(6):939-948.
85. Goletz T., Mackall C.L., Berzofsky J.A., et al. Molecular alterations in pediatric sarcomas: potential targets for immunotherapy. Sarcoma 1998, 2:77-87.